The current year has been mainly characterized by the publication in Europe of the guidelines on the diagnosis and treatment of heart failure (HF) and in USA by an update on pharmacological treatment of HF with the praiseworthy effort to provide consistent recommendations on drug therapy (1–3). Therefore, the large majority of new evidences published at the end of 2015 and in the first quarter of 2016 are included in these publications. ...